- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05599061
Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial (VULNERABLE)
April 19, 2024 updated by: Fundación EPIC
Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Randomized Trial
The study aims to compare a preventive percutaneous coronary intervention (PCI) plus optimal medical treatment (OMT) strategy vs. OMT for treatment of non-functionally significant non-culprit lesions presenting with optical coherence tomography (OCT) findings indicative of vulnerable plaque, in patients with ST-elevation myocardial infarction (STEMI) and multivessel disease.
Study Overview
Status
Recruiting
Detailed Description
STEMI patients with multivessel disease planned for invasive evaluation of intermediate lesions (40-69% stenosis) are initially investigated with fractional flow reserve (FFR).
Patients with FFR ≤ 0.80 are considered as screening failure and treated with PCI.
Patients with FFR > 0.80 are then investigated with optical coherence tomography (OCT).
Patients without OCT findings of vulnerable plaque are treated with OMT and included in the OMT registry arm.
Patients presenting with OCT characteristics of vulnerable plaque are included in the randomized trial comparing PCI with stent implantation plus OMT versus OMT.
Study Type
Interventional
Enrollment (Estimated)
600
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Josep Gomez-Lara, MD, PhD
- Phone Number: 0034677255399
- Email: gomezjosep@hotmail.com
Study Contact Backup
- Name: FUNDACION EPIC
- Phone Number: 0034987225638
- Email: iepic@fundacionepic.org
Study Locations
-
-
-
Albacete, Spain, 02006
- Recruiting
- Hospital General Universitario de Albacete
-
Alicante, Spain, 03010
- Recruiting
- Hospital General Universitario Dr.Balmis
-
Alicante, Spain, 03550
- Recruiting
- Hospital Universitari Sant Joan D'Alacant
-
Badalona, Spain, 08916
- Recruiting
- Hospital Universitari Germans Trias i Pujol
-
Barcelona, Spain, 08003
- Recruiting
- Hospital del Mar
-
Barcelona, Spain, 08036
- Recruiting
- Hospital Clínic de Barcelona
-
Barcelona, Spain, 08025
- Recruiting
- Hospital de Santa Creu I Sant Pau
-
Cadiz, Spain, 11009
- Recruiting
- Hospital Universitario Puerta Del Mar
-
Castellón De La Plana, Spain, 12004
- Recruiting
- Hospital General Universitario de Castellón
-
Ciudad Real, Spain, 13005
- Recruiting
- Hospital General Universitario de Ciudad Real
-
Coruña, Spain, 15006
- Recruiting
- Hospital Universitario A Coruña
-
Córdoba, Spain, 14004
- Recruiting
- Hospital Universitario Reina Sofia de Cordoba
-
Elche, Spain, 03203
- Recruiting
- Hospital General Universitario de Elche
-
Gijón, Spain, 33394
- Recruiting
- Hospital Universitario de Cabueñes
-
Girona, Spain, 17007
- Recruiting
- Hospital Universitario de Girona Dr Trueta
-
Granada, Spain, 18016
- Recruiting
- Hospital Universitario San Cecilio
-
Huelva, Spain, 21005
- Recruiting
- Hospital Universitario Juan Ramon Jimenez
-
León, Spain, 24001
- Recruiting
- Hospital Universitario de Leon
-
Madrid, Spain, 28046
- Recruiting
- Hospital Universitario La Paz
-
Madrid, Spain, 28007
- Recruiting
- Hospital Universitario Gregorio Marañon
-
Madrid, Spain, 28006
- Recruiting
- Hospital La Princesa
-
Majadahonda, Spain, 28222
- Recruiting
- Hospital Universitario Puerta de Hierro
-
Manises, Spain, 46940
- Recruiting
- Hospital de Manises
-
Murcia, Spain, 30120
- Recruiting
- Hospital Universitario Virgen Arrixaca
-
Oviedo, Spain, 33011
- Recruiting
- Hospital Universitario Central de Asturias
-
Palma De Mallorca, Spain, 07120
- Recruiting
- Hospital Universitari Son Espases
-
Pamplona, Spain, 31008
- Recruiting
- Hospital Universitario de Navarra
-
Salamanca, Spain, 37007
- Recruiting
- Hospital Clínico Universitario de Salamanca
-
San Sebastián, Spain, 20014
- Recruiting
- Hospital Universitario de Donostia
-
Santander, Spain, 39008
- Recruiting
- Hospital Universitario Marqués de Valdecilla
-
Santiago De Compostela, Spain, 15706
- Recruiting
- Hospital Clinico Universitario de Santiago de Compostela
-
Sevilla, Spain, 41013
- Recruiting
- Hospital Universitario Virgen del Rocio
-
Tarragona, Spain, 43005
- Recruiting
- Hospital Universitari Joan Xxiii
-
Torrevieja, Spain, 03186
- Recruiting
- Hospital Universitario de Torrevieja
-
Valencia, Spain, 46010
- Recruiting
- Hospital Clinico Universitario de Valencia
-
Valencia, Spain, 46026
- Recruiting
- Hospital Universitari i Politecnic La Fe
-
Valencia, Spain, 46014
- Recruiting
- Hospital General Universitario de Valencia
-
Valladolid, Spain, 47003
- Recruiting
- Hospital Clínico Universitario de Valladolid
-
Zaragoza, Spain, 50009
- Recruiting
- Hospital Clinico Universitario Lozano Blesa
-
Zaragoza, Spain, 50009
- Recruiting
- Hospital Universitari Miquel Servet
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain, 08907
- Recruiting
- Hospital Universitari de Bellvitge
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients > 18 years.
- Successful revascularization of the culprit lesion in patients undergoing coronary angiography due to ST-segment elevation (> 1mm in > 2 contiguous leads, new left bundle branch block, or true posterior MI with ST depression of >1mm in >2 contiguous anterior leads) in the first 72 hours of the symptom's onset.
- Multivessel coronary disease with non-culprit lesions located in different vessels than the culprit lesion and ranging from 40 to 69% of DS (visual estimated diameter stenosis ) by visual estimate planned for FFR-guided revascularization in staged procedure (>24 hours and <60 days after PCI of the culprit lesion).
- Non-culprit lesions should be suitable for functional assessment with pressure wire and OCT catheter and should be suitable to be treated with a single 2.0 to 4.5 mm EES (everolimus-eluting stent ).
- Subject agrees to not participate in any other clinical trial study for a period of 4 years following the inclusion in the study.
- Informed consent signed.
Exclusion Criteria:
- Inability to provide informed consent.
- Female of childbearing potential (age <50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.
- Known intolerance to aspirin, heparin, everolimus, contrast material.
- Unresolved mechanical complication or cardiogenic shock at the staged procedure.
- Non-culprit study lesions located in the left main coronary artery or in coronary vessels with prior coronary revascularization (PCI or by-pass) or with distal vessel occlusion.
- Patients with long, bifurcated, severely angulated or severely calcified non-culprit study lesions non suitable to be treated with a single EES implantation.
- Asthma or known history of bronchial hyper-reactivity.
- Chronic renal dysfunction with creatinine clearance < 45 ml/min.
- Severe comorbidities that in the opinion of the local investigators determine the patient's life expectancy < 4 years.
- Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Optimal Medical Treatment (OMT) + PCI
|
Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI
OPTIMAL MEDICAL TREATMENT (OMT)
|
Active Comparator: Optimal Medical Treatment (OMT)
|
Patients received OPTIMAL MEDICAL TREATMENT (OMT)+PCI
OPTIMAL MEDICAL TREATMENT (OMT)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target Vessel Failure (TVF)
Time Frame: 4 Years
|
TVF as a composite of : Cardiovascular Death Target-vessel related MI Clinically and physiologically-oriented Target vessel revascularization |
4 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiac death
Time Frame: 4 Years
|
To compare Cardiac death between both groups in the randomized arm death.
|
4 Years
|
All-cause Death
Time Frame: 4 Years
|
To compare all death between both groups in the randomized arm death.
|
4 Years
|
All Myocardial Infarctions
Time Frame: 4 Years
|
To compare Myocardial Infarctions between both groups in the randomized arm death.
death
|
4 Years
|
Target-Vessel Myocardial Infarction
Time Frame: 4 Years
|
To compare target-vessel myocardial infarction between both groups in the randomized arm.
|
4 Years
|
Revascularizations
Time Frame: 4 Years
|
To compare all revascularizations between both groups in the randomized arm.
|
4 Years
|
Ischemic-driven target vessel revascularization
Time Frame: 4 Years
|
To compare ischemic-driven target vessel revascularization between both groups in the randomized arm.
|
4 Years
|
Patient-oriented endpoint of major adverse cardiac events
Time Frame: 4 Years
|
To compare the patient-oriented endpoint of major adverse cardiac events, a composite of all-cause death, myocardial infarction, and revascularization between both groups in the randomized arm.
|
4 Years
|
Target Vessel Failure (TVF)
Time Frame: 4 Years
|
To compare the TVF rate between patients included in the OMT group of the randomized arm (presenting with vulnerable plaque) vs. patients included in the OMT registry (without vulnerable plaque).
|
4 Years
|
Fractional Flow Reserve (FFR)
Time Frame: 4 years
|
To compare the FFR values between patients with vulnerable plaques (randomized arm) and patients without vulnerable plaques (OMT registry).
|
4 years
|
Minimal lumen area by Optical Coherence Tomography (OCT)
Time Frame: 4 years
|
To establish the optimal OCT-derived minimal lumen area cutoff to predict an ischemic FFR in the non-culprit artery in the acute setting.
|
4 years
|
Accuracy of vulnerable plaque assessment by Optical Coherence Tomography (OCT)
Time Frame: 4 years
|
To compare the agreement between local operators and the core-laboratory to assess vulnerable plaques by OCT.
|
4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B, Di Pasquale G, Lopez-Sendon J, Faxon DP, Mauri L, Rao SV, Feldman L, Steg PG, Avezum A, Sheth T, Pinilla-Echeverri N, Moreno R, Campo G, Wrigley B, Kedev S, Sutton A, Oliver R, Rodes-Cabau J, Stankovic G, Welsh R, Lavi S, Cantor WJ, Wang J, Nakamya J, Bangdiwala SI, Cairns JA; COMPLETE Trial Steering Committee and Investigators. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019 Oct 10;381(15):1411-1421. doi: 10.1056/NEJMoa1907775. Epub 2019 Sep 1.
- Erlinge D, Maehara A, Ben-Yehuda O, Botker HE, Maeng M, Kjoller-Hansen L, Engstrom T, Matsumura M, Crowley A, Dressler O, Mintz GS, Frobert O, Persson J, Wiseth R, Larsen AI, Okkels Jensen L, Nordrehaug JE, Bleie O, Omerovic E, Held C, James SK, Ali ZA, Muller JE, Stone GW; PROSPECT II Investigators. Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. Lancet. 2021 Mar 13;397(10278):985-995. doi: 10.1016/S0140-6736(21)00249-X.
- Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, le Bras A, Gallet R, Khalife K, Morelle JF, Motreff P, Lemesle G, Dillinger JG, Lhermusier T, Silvain J, Roule V, Labeque JN, Range G, Ducrocq G, Cottin Y, Blanchard D, Charles Nelson A, De Bruyne B, Chatellier G, Danchin N; FLOWER-MI Study Investigators. Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. N Engl J Med. 2021 Jul 22;385(4):297-308. doi: 10.1056/NEJMoa2104650. Epub 2021 May 16.
- Stone GW, Maehara A, Ali ZA, Held C, Matsumura M, Kjoller-Hansen L, Botker HE, Maeng M, Engstrom T, Wiseth R, Persson J, Trovik T, Jensen U, James SK, Mintz GS, Dressler O, Crowley A, Ben-Yehuda O, Erlinge D; PROSPECT ABSORB Investigators. Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque. J Am Coll Cardiol. 2020 Nov 17;76(20):2289-2301. doi: 10.1016/j.jacc.2020.09.547. Epub 2020 Oct 15.
- Denormandie P, Simon T, Cayla G, Steg PG, Montalescot G, Durand-Zaleski I, le Bras A, le Breton H, Valy Y, Schiele F, Cuisset T, Vanzetto G, Levesque S, Goube P, Nallet O, Angoulvant D, Roubille F, Charles Nelson A, Chatellier G, Danchin N, Puymirat E. Compared Outcomes of ST-Segment-Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial. Circ Cardiovasc Interv. 2021 Nov;14(11):e011314. doi: 10.1161/CIRCINTERVENTIONS.121.011314. Epub 2021 Aug 23.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 30, 2023
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
December 1, 2028
Study Registration Dates
First Submitted
October 25, 2022
First Submitted That Met QC Criteria
October 25, 2022
First Posted (Actual)
October 31, 2022
Study Record Updates
Last Update Posted (Actual)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 19, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPIC28-VULNERABLE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina